Analysts Set Dyne Therapeutics, Inc. (NASDAQ:DYN) PT at $35.21

Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) have received an average rating of “Moderate Buy” from the seventeen research firms that are covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recommendation, eleven have assigned a buy recommendation and three have issued a strong buy recommendation on the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $35.00.

DYN has been the subject of several analyst reports. Evercore set a $33.00 price target on Dyne Therapeutics in a report on Friday, May 15th. Jefferies Financial Group restated a “buy” rating on shares of Dyne Therapeutics in a report on Monday, March 9th. Chardan Capital restated a “buy” rating and set a $38.00 price objective on shares of Dyne Therapeutics in a report on Monday, March 9th. Wall Street Zen upgraded Dyne Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, May 16th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Dyne Therapeutics in a report on Monday, April 20th.

Dyne Therapeutics Trading Up 10.3%

Shares of DYN opened at $17.56 on Thursday. The stock has a fifty day moving average of $18.38 and a two-hundred day moving average of $18.44. The company has a debt-to-equity ratio of 0.17, a quick ratio of 19.92 and a current ratio of 19.92. The company has a market capitalization of $2.90 billion, a PE ratio of -5.45 and a beta of 1.08. Dyne Therapeutics has a fifty-two week low of $8.06 and a fifty-two week high of $25.00.

Dyne Therapeutics (NASDAQ:DYN) last issued its quarterly earnings results on Monday, May 11th. The company reported ($0.73) earnings per share for the quarter, beating the consensus estimate of ($0.77) by $0.04. During the same period last year, the company earned ($1.05) earnings per share. As a group, analysts forecast that Dyne Therapeutics will post -2.99 EPS for the current year.

Insider Buying and Selling at Dyne Therapeutics

In related news, Director Jason P. Rhodes sold 83,219 shares of the company’s stock in a transaction on Wednesday, May 6th. The shares were sold at an average price of $18.18, for a total transaction of $1,512,921.42. Following the completion of the sale, the director directly owned 7,962 shares of the company’s stock, valued at approximately $144,749.16. This represents a 91.27% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO John Cox sold 3,311 shares of the company’s stock in a transaction on Wednesday, May 13th. The stock was sold at an average price of $18.36, for a total transaction of $60,789.96. Following the sale, the chief executive officer directly owned 370,834 shares of the company’s stock, valued at approximately $6,808,512.24. This trade represents a 0.88% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 1,559,462 shares of company stock valued at $29,814,746 in the last quarter. Company insiders own 14.14% of the company’s stock.

Institutional Trading of Dyne Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the business. Creative Planning boosted its position in Dyne Therapeutics by 6.8% in the 3rd quarter. Creative Planning now owns 15,527 shares of the company’s stock valued at $196,000 after buying an additional 986 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Dyne Therapeutics by 25.3% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,500 shares of the company’s stock valued at $70,000 after acquiring an additional 1,109 shares in the last quarter. Hilton Head Capital Partners LLC acquired a new stake in shares of Dyne Therapeutics during the first quarter valued at about $26,000. Caxton Associates LLP grew its stake in shares of Dyne Therapeutics by 10.9% during the second quarter. Caxton Associates LLP now owns 16,599 shares of the company’s stock valued at $158,000 after acquiring an additional 1,627 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. grew its stake in shares of Dyne Therapeutics by 9.2% during the third quarter. China Universal Asset Management Co. Ltd. now owns 24,937 shares of the company’s stock valued at $315,000 after acquiring an additional 2,108 shares in the last quarter. 96.68% of the stock is owned by hedge funds and other institutional investors.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor?mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.